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Background: The aim of this study is to investigate the expression of apolipoprotein E (apoE) and the relationship
between apoE and disease activity of SLE, and the possible effects of glucocorticoid on apoE and other cytokines
activities in SLE patients.
Methods: Forty treatment-naïve SLE patients and forty matched healthy controls were studied. All the SLE patients
received prednisone 1 mg/kg/day for 28 consecutive days. The sera levels of apoE and related cytokines were
evaluated by ELISA. The expression of apoE mRNA in peripheral blood mononuclear cells (PBMCs) was determined
by real-time PCR.
Results: Compared with healthy controls, the relative expression levels of ApoE proteins and sera levels were
significantly up-regulated in active SLE patients. ApoE sera concentrations positively correlated with SLEDAI, anti-dsDNA
antibody and the related cytokines including IL-6, IFN-γ and IL-10, and uncorrelated with the concentration of total
cholesterol (TC) and triglyceride (TG) in SLE patients. After 4 weeks prednisone treatment, the relative mRNA
expression of apoE and the serum levels of apoE and related cytokines decreased.
Conclusions: ApoE correlated with disease activity and related cytokines in SLE patients. Glucocorticoid can
down-regulate the expressions of apoE and related cytokines.
Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1646714011077325
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Systemic lupus erythematosus (SLE) is a multisystem in-
flammatory and autoimmune disease. Despite the etiology
of SLE has not been fully understood, the abnormal
lymphocyte apoptosis, decreased clearance of activated T
cells and involvement of multiple cytokines including
IFN-γ [1], interleukin (IL)-10 [1] and IL-6 [2] have been
demonstrated with the pathogenesis of SLE [3-5].
Apolipoprotein (apo) E is a multifunctional glycoprotein
synthesized chiefly by the liver and the macrophage. It is
implicated in human lipoprotein metabolism and cardio-* Correspondence: rheum_666@163.com
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stated.vascular disease [6]. Increasing studies have proved that
apoE plays a key role in inhibiting the proliferation of T
lymphocytes, regulating immune reactions and interacting
with several cytokines [7-10]. Moreover, it has been sug-
gested that apoE might play a pivotal role in modulating
inflammatory and immune response in autoimmune dis-
eases like multiple sclerosis (MS) and rheumatoid arthritis
[11,12]. These lines of evidence indicate that apoE may
play an important role in the pathogenesis of SLE.
Glucocorticoid remains the cornerstone of the treat-
ment of SLE, despite advances in therapeutic protocols
and development of new drugs [13]. GCs reduce the
synthesis of pro-inflammatory cytokines, such as IL-6,
tumor necrosis factor (TNF)-α [14] and anti-inflamma-
tory cytokines such as IL-37 [15]. However, the effect of
glucocorticoid on apoE remains unclear.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Clinical and demographic features of the studied
subjects





No. of cases 40 40 40
Female, n (%) 36 (90.0%) 36 (90.0%) 36 (90.0%)
Male, n (%) 4 (10%) 4 (10%) 4 (10%)
Age, years (range) 33.7 (20 ~ 55) 33.7 (20 ~ 55) 34.8 (21 ~ 57)
Course of disease months 11.2 (1 ~ 26) 12.2 (2 ~ 27) -
(range)
SLEDAI (mean ± SD) 11.45 ± 3.76 7.90 ± 4.00 -
Skin and mucosa lesion 28 (70.0%) 15 (37.5%0) -
Serositis, n (%) 15 (37.5%) 8 (20.0%) -
Arthritis, n (%) 18 (45.0%) 4 (10.0%) -
Lupus nephritis, n (%) 24 (60.0%) 20 (50%) -
Hematologic involvement 25 (62.5%) 9 (22.5%) -
NPSLE, n (%) 1 (2.5%) 0 -
ANA, n (%) 40 (100%) 39 (97.5%) 0
Anti-dsDNA antibody, (%) 18 (45.0%) 14 (35.0%) 0
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mRNA in peripheral blood mononuclear cells (PBMCs)
and serum protein levels in SLE patients with healthy
controls. In addition, we examined the disease activity
using SLE disease activity index (SLEDAI) [16], anti-
dsDNA antibody, IFN-γ, IL-6 and IL-10 in SLE to deter-
mine whether apoE is involved in the pathogenesis of
SLE, and the possible effects of glucocorticoid on apoE
and other cytokines activities in SLE patients.
Materials and methods
Subjects
Forty SLE patients (36 females and 4 males; range: 20 ~
55 yrs) with systemic lupus erythematosus disease activ-
ity index (SLEDAI) ≥ 5 [16] were recruited into the
present study. All patients who had visited the rheuma-
tology ward of Qilu Hospital of Shandong University
from November 2011 to October 2012 fulfilled the
American College of Rheumatology (ACR) 1997 revised
criteria for SLE [17]. Individuals with any other rheum-
atic diseases were excluded from the study. None of
them had been treated with GCs or other immunosup-
pressive drugs prior to first collection of specimens. All
of them received prednisone 1 mg/kg/day for 28 con-
secutive days. Forty sex- and age-matched healthy con-
trols (36 females and 4 males; range: 21 ~ 57 yrs) were
recruited into the present study, all of whom did not
have any rheumatic conditions and dyslipidemia-related
diseases. The study protocol was approved by the ethics
committee of Qilu Hospital of Shandong University (No.
12126). All participants gave their informed consent for
blood sampling.
Blood samples
Peripheral venous blood was collected from each SLE
patient and control subject. Samples were centrifuged at
3000 r/min for 5 minutes, and serum samples were
stored at −80°C until use.
Quantitative real-time polymerase chain reaction (RT -PCR)
Mononuclear cells were separated from heparinized
blood with NycoPrep™1.077 (Axis-Shield, Norway) gradi-
ent centrifuge technique. Total RNA was extracted by
Trizol Reagent (Invitrogen, America) according to in-
structions of the manufacturer. Approximately 1 μg of
total RNA in 20 μg reactions was reversely transcribed to
cDNA and 1.0 μg cDNA was used in the qRT-PCR proce.
Primer sequences used for the RT-PCR were as follows:
ApoE, 5′- CTG CGT TGC TGG TCA CAT TC -3′
(forward), 5′- CTG GTG GGT TCT CCT TAT TG -3′
(reverse); and GAPDH, 5′- ACC ACA GTC CAT GCC
ATC AC -3′ (forward), 5′- TCC ACC ACC CTG TTG
CTG TA -3′ (reverse). Real-time PCR was performed
using the SYBR Green I real-time PCR kit (TAKARA,Dalian, China) in an ABI PRISM 7300 Sequence Detector
(Perkin-Elmer, Norwalk, CT, USA). The reaction was
carried out for 40 cycles at 95°C for 5 s, 60°C for 45 s and
72°C for 45 s. Each sample was run in triplicate. The
PCR products were separated in an agarose gel and to
confirm the expected size in all cases. A melting-curve
analysis was also performed to ensure specificity of the
products. The relative expression level of ApoE was calcu-
lated with comparative threshold cycle (Ct) method and
evaluated by:
2−ΔΔCt;ΔΔCt ¼ Patient CtApoE−CtGAPDH
 
−Mean of controls CtApoE−CtGAPDH
 
Enzyme-linked immunosorbent assay (ELISA)
Determinations of serum apoE, IL-6, IFN-γ and IL-10
levels were quantified by ELISA, following the manufac-
turer’s instructions (Yonghui, Beijing, China). Detection
of anti-dsDNA antibody was also quantified by ELISA
which is becoming the most widely used method and
has high sensitivity [18].
Statistical analysis
Statistical analysis was performed using SPSS13.0. Data
were expressed as mean ± SD when normally distributed
and median ± IQR when non-normally distributed. All
the data were analyzed with the non-parameter test. The
Figure 1 Relative mRNA expressions of apoE in SLE patients (pre-treatment patients and post-treatment patients) and healthy
controls. Freshly isolated human PBMCs from SLE patients and healthy controls were quantified by RT-PCR. *, p < 0.05, Pre-treatment SLE patients
vs. healthy controls; #, p < 0.05, Pre-treatment SLE patients vs. post-treatment SLE patients; &, p < 0.05, Post-treatment SLE patients vs.
healthy controls.
Table 2 The serum levers of apoE and other cytokines
[pg/ml, M (Q1, Q3)]
Items SLE patients Controls
Pre-treatment Post-treatment
N 40 40 40
ApoE 18.31 (13.09, 45.37)*# 12.95 (8.03, 30.50)& 8.10 (5.94, 10.81)
IL-6 0.86 (0.70, 1.72)*# 0.72 (0.58, 1.18) 0.67 (0.51, 0.82)
IFN-γ 41.06 (33.25, 118.51)*# 33.85 (17.00, 56.08) 34.61 (29.12, 43.23)
IL-10 39.35 (31.94, 92.33)*# 33.85 (17.33, 58.80) 31.82 (23.46, 44.48)
Note: *, p < 0.05, SLE (pre-treatment) compared with normal controls;
#, p < 0.05, SLE (pre-treatment) compared with SLE (post-treatment); &, p < 0.05,
SLE (post-treatment) compared with normal controls.
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control group were performed by independent sample
nonparametric tests. The correlations between apoE
levels and SLEDAI, anti-dsDNA antibody, cytokines or
serum lipid were analyzed by Spearman rank correlation.
P < 0.05 was considered to be significant.
Results
Clinical characteristics of patients with SLE
The clinical and demographic features of SLE patients and
healthy controls were shown in Table 1. The SLEDAI
scores ranged from 11.45 ± 3.76 of pre-treatment to
7.90 ± 4.00 of post-treatment (p < 0.01). After prednisone
treatment, the anti-dsDNA antibodies decreased signifi-
cantly compared to the levels before treatment. The skin
and mucosa lesion, hematological involvement, lupus
nephritis, arthritis and serositis were the major manifesta-
tions in the present studied SLE patients.
ApoE mRNA expression in SLE patients and controls
Using the IQ5 software, the data were presented as the
fold change in gene expression normalized to GAPDH.
The relative expression of apoE mRNA in pre-treatment
SLE patients increased by 3.44-fold compared with
healthy controls (p < 0.05). After 4 weeks prednisone
treatment, the relative expression of apoE mRNA de-
creased to 2.15-fold compared with healthy controls
(p < 0.05) (Figure 1).
Serum apoE, IL-6, IFN-γ and IL-10 levels in SLE patients
and controls
As shown in Table 2, the plasma levels of all the tested
cytokines including apoE, IL-6, IFN-γ and IL-10 in pre-treatment SLE patients were significantly up-regulated
compared with healthy controls (p < 0.05). The levels of
apoE, IL-6, IFN-γ and IL-10 were significantly decreased
in the SLE patients after prednisone treatments.
Correlation of serum apoE levels with disease activity and
related cytokines in SLE patients and healthy controls
ApoE levels revealed positive correlation with anti-
dsDNA antibody in both pre-treatment SLE patients
(r = 0.64, p < 0.01) and post-treatment patients (r = 0.56,
p < 0.01) (Figure 2). Furthermore, a strong correlation
was found between apoE sera levels and SLEDAI in pre-
treatment patients (r = 0.71, p < 0.01) and post-treatment
patients (r = 0.65, p < 0.01) (Figure 2). The sera apoE
concentrations positively correlated with IL-6 (r = 0.57,
p < 0.01), IFN-γ (r = 0.78, p < 0.01) and IL-10 (r = 0.76,
p < 0.01) in pre-treatment SLE patients. After prednisone
treatment, the sera apoE concentrations still positively
correlated with IL-6 (r = 0.54, p < 0.01), IFN-γ (r = 0.82,
p < 0.01) and IL-10 (r = 0.70, p < 0.01) (Figure 3). In
Figure 2 Spearman rank correlation analysis of apoE with anti-dsDNA antibody and SLEDAI in SLE patients. The sera apoE
concentrations were positively correlated with anti-dsDNA antibody (r = 0.64, p < 0.01) and SLEDAI (r = 0.71, p < 0.01) in pre-treatment SLE
patients. After prednisone treatment, the sera apoE concentrations were still positively correlated with anti-dsDNA antibody (r = 0.56, p < 0.01)
and SLEDAI (r = 0.65, p < 0.01).
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positively correlated with IL-6 (r = 0.87, p < 0.01), IFN-γ
(r = 0.68, p < 0.01) and IL-10 (r = 0.72, p < 0.01).Correlations of ApoE with TC and TG in SLE patients
No statistically significant relationships between apoE
and TC (r = 0.413, p = 0.435) or TG (r = 0.350, p = 0.724)
were found in patients with SLE.Discussion
The results of the present studies show that apoE mRNA
expression is increased in active SLE patients. The levels
of apoE mRNA were low in stable SLE and healthy con-
trols. In a similar way, the serum levels of IL-6, IFN-γ
and IL-10 were also significantly increased in active SLE
patients and low in stable SLE patients. These data indi-
cate that apoE and related cytokines including IL-6,IFN-γ and IL-10 might take part in the pathogenesis of
SLE.
ApoE is primarily synthesized in liver and brain astro-
cytes [19], however, it can also be produced by a wide
variety of tissues including monocytes [20], adrenals and
kidneys [21]. ApoE plays a vital role in modulating in-
flammation and oxidation since the function of apoE is
closely linked with both pro-inflammatory and anti-
inflammatory cytokines [6,10]. It has been reported that
apoE-deficient (apoE−/−) macrophages ingest fewer
apoptotic lymphocytes than wild type macrophages in
animal experiment. What’s more, there is markedly T
lymphocyte activating and attenuated initial immune re-
sponse in apoE−/− mice compared with wild type [22].
Several researches have confirmed that multiple cyto-
kines such as IFN-γ [1,23], IL-10 [1,24] and IL-6 [2,24]
take part in the pathogenesis of SLE by contributing
to inflammatory and immunological responses. The
Figure 3 Spearman rank correlation analysis of apoE with IL-6, IFN-γ and IL-10 in SLE patients. The sera apoE concentrations positively
correlated with IL-6 (r = 0.57, p < 0.01), IFN-γ (r = 0.78, p < 0.01) and IL-10 (r = 0.76, p < 0.01) in pre-treatment SLE patients. After prednisone
treatment, the sera apoE concentrations still positively correlated with IL-6 (r = 0.54, p < 0.01), IFN-γ (r = 0.82, p < 0.01) and IL-10 (r = 0.70, p < 0.01).
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production in apoE−/− mice have been shown in some
report [8]. Inflammatory cytokine levels obviously de-
creased by injecting exogenous apoE [11]. Using IFN-γ
to stimulate apoE−/−and apoE+/+ mice, the expressions
of CD40, CD80 and the major histocompatibility com-
plex class (MHC) II molecules on macrophages in
apoE−/− mice were increased compared with ApoE+/+
[25]. This indicates that apoE at physiological level can
affect antigen-presenting function and inhibit activation
of T cells by down regulating the expression of MHCII
and co-stimulatory molecules on antigen-presenting
cells processed by IFN-γ. Taken together, apoE functions
as anti-inflammatory cytokine in vivo and plays an im-
portant role in negative immune regulation.
The maintenance of immune homeostasis depends on
the balance of pro-inflammatory cytokines and anti-
inflammatory cytokines. The imbalance of immune
system potentially results in the development of auto-
immune disorders. It has been reported that multiple cy-
tokines including pro-inflammatory such as IL-6 and
IFN-γ [15] and anti-inflammatory cytokines such as IL-10
[26] and progranulin protein (PGRN) [27] and multiple
immunocytes such as Treg [28], Th17 [29] and B cell [30]
contribute to the pathogenesis of SLE. Our present study
finds that apoE is elevated in active SLE patients accom-
panying the increase of IFN-γ, IL-6 and IL-10 and
strongly correlated with IFN-γ, IL-6 and IL-10 serum
levels. Based on the strong correlations between apoE andthe above cytokines in SLE patients, we speculate that
apoE may have an anti-inflammatory and immunoregula-
tory effect in SLE patients by interacting with other
cytokines. The increase of apoE resulting from the
increase of pro-inflammatory cytokines is a compensatory
reaction; however, this compensation usually cannot fully
antagonize the effect of pro-inflammatory cytokines,
which partially lead to the development of SLE. The posi-
tive correlations between apoE and IFN-γ, IL-6 and IL-10
in healthy controls and active SLE indicate that both pro-
inflammatory and anti-inflammatory cytokines keep the
balance to the greatest extent in steady and active state.
In this study, our data clearly show that serum levels
of apoE are closely correlated with SLEDAI scores as
well as anti-dsDNA antibody levels. SLEDAI is the most
widely accepted clinical model for SLE disease activity in
most countries [31]. In addition, anti-dsDNA antibody
plays a crucial role in the pathogenesis of SLE and is be-
lieved to be one of the evaluating factors of SLE disease
[32]. It has been reported that both pro-inflammatory
and anti-inflammatory cytokines increased accompany-
ing the increase of SLEDAI score and anti-dsDNA
antibody in active SLE [15,27]. SLEDAI score and anti-
dsDNA antibody are closely related with SLE disease ac-
tivity and apoE positively correlated with SLEDAI score
and anti-dsDNA antibody, which means the aberrant ex-
pressions of apoE were related with SLE disease activity.
Glucocorticoid can inhibit Th1 cytokine production in
T cells and potentially enhance Th2 cytokine synthesis in
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cytoplasmic glucocorticoid receptors and forms recep-
tor-corticosteroid complex, which translocates to the nu-
cleus and regulates the transcription of target genes [36].
The present study found that glucocorticoid can affect
the serum levels of both pro-inflammatory and anti-
inflammatory cytokines, which accords with our previ-
ous studies [15,27].
ApoE is mainly presented with the lipoprotein bound
form, found in chylomicrons, very low density lipopro-
teins, and high density lipoproteins, as well as a key regu-
lator of lipid and cholesterol metabolism [37,38]. In our
present study, there are no correlations between apoE and
TC or TG, which is maybe due to the polymorphism of
apoE gene [39,40]. The relationship between polymor-
phisms of apoE gene and disease activity and related cyto-
kines in SLE will be the key in our next study.
In conclusion, the present data demonstrate that apoE is
up-regulated in active SLE patients. ApoE positively corre-
lates with SLEDAI, anti-dsDNA antibody and related cyto-
kines such as IL-6, IFN-γ and IL-10, which indicates that
apoE is closely related with SLE disease activity and prob-
able is involved in the pathogenesis of SLE.
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